Defitelio

• Defitelio is a medication used to treat severe hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction, a serious complication of stem cell transplantation.
• It works by protecting endothelial cells and restoring the balance in blood clot formation and breakdown within blood vessels.
• Common Defitelio side effects include bleeding, hypotension, and gastrointestinal issues.
• Close monitoring for bleeding and allergic reactions is essential during treatment with this medication.
• Defitelio drug information highlights its intravenous administration and the need for careful dose adjustment based on the patient’s condition.

What is Defitelio? Uses & How It Works

Defitelio is a complex mixture of single-stranded deoxyribonucleotides derived from porcine intestinal mucosa. It is classified as a defibrotide, a medication with antithrombotic and profibrinolytic properties, meaning it helps prevent and break down blood clots, while also protecting the endothelial cells lining blood vessels.

The primary indication for what is Defitelio used for is the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT). VOD is a life-threatening complication where small veins in the liver become blocked, leading to liver damage and fluid retention. The European Society for Blood and Marrow Transplantation (EBMT) reports that severe VOD can have a mortality rate exceeding 80% if untreated, underscoring the critical role of medications like Defitelio.

The exact mechanism of how does Defitelio work is not fully understood, but it is believed to exert its therapeutic effects primarily by protecting and restoring the integrity of endothelial cells, which form the inner lining of blood vessels. In VOD, these cells are damaged, leading to inflammation, clot formation, and obstruction of hepatic sinusoids. Defitelio is thought to enhance the activity of enzymes involved in fibrinolysis (the breakdown of blood clots) and to reduce the adhesion of platelets and white blood cells to damaged endothelium. It also modulates the release of pro-inflammatory mediators, thereby reducing overall vascular damage and promoting the restoration of normal blood flow through the liver.

Defitelio Side Effects & Important Drug Info

Like all medications, Defitelio can cause side effects. The most common Defitelio side effects are related to its anticoagulant and profibrinolytic properties, which can increase the risk of bleeding. Patients may experience hemorrhage, including gastrointestinal, pulmonary, or cerebral bleeding. Other frequently reported side effects include hypotension (low blood pressure), diarrhea, nausea, vomiting, and sepsis. Less common but serious side effects can include hypersensitivity reactions, such as rash or anaphylaxis. Due to the potential for serious bleeding, patients receiving Defitelio require close monitoring throughout their treatment.

Here are some common side effects to be aware of:

• Bleeding (e.g., gastrointestinal, pulmonary, cerebral)
• Hypotension (low blood pressure)
• Diarrhea
• Nausea and vomiting
• Sepsis
• Hypersensitivity reactions (e.g., rash, anaphylaxis)

Defitelio drug information emphasizes its intravenous administration. It is supplied as a sterile, preservative-free solution for infusion and must be diluted before use. The dosage is typically based on the patient’s body weight and is administered multiple times daily. Treatment duration usually continues until VOD symptoms resolve or for a maximum of 21 days, though extensions may be considered. It is crucial for healthcare professionals to assess a patient’s coagulation status, including platelet count and other clotting parameters, before and during treatment to manage the risk of bleeding. Defitelio should be used with caution in patients with active bleeding or those receiving other anticoagulant medications, as this can further increase the risk of hemorrhage. The medication is generally contraindicated in patients with known hypersensitivity to defibrotide or any component of the formulation.